Search results for "g factor"

showing 10 items of 514 documents

The impact of two whole blood inline filters on markers of coagulation, complement and cell activation

2005

Background and Objectives  There exists a current lack of information about the impact of different inline filters, used for the leucoreduction of whole blood (WB), on the levels of clotting factors and markers of coagulation, complement and cell activation in plasma. Only a few small comparisons of different types of WB inline filters have been published to date. Materials and Methods  This study compared two plasma types of 200 units each. Both study groups were derived from WB, inline-filtered and held for 2 h at 20° between donation and filtration. Then, 200 units (Group A) were filtered using a positively charged polyester filter (Baxter RZ2000) and the other 200 units (Group B) were f…

AdultMaleAdolescentFibrinogenNeutrophil ActivationThrombinmedicineHumansPlateletBlood CoagulationComplement ActivationAgedWhole bloodClotting factorChemistryHematologyGeneral MedicineMiddle AgedPlatelet ActivationMolecular biologyComplement systemImmunologyFemaleLeukocyte Reduction ProceduresCell activationBiomarkersFiltrationPlatelet factor 4medicine.drugVox Sanguinis
researchProduct

Comparison between once a day vs twice a day G-CSF for mobilization of peripheral blood progenitor cells (PBPC) in normal donors for allogeneic PBPC …

1998

Despite the wide use of G-CSF for mobilization of PBPC the best dose and schedule of G-CSF has not been definitively established. In this study we have compared three different schedules of G-CSF for mobilization of PBPC in normal donors including a single daily dose of 10 microg/kg/day for 5 days (21 donors) and doses of 6 (21 donors) or 8 microg/kg/12 h (6 donors) for 5 days. We demonstrate that G-CSF at doses of 6 and 8 microg/kg/12 h mobilizes significantly more CD34+ cells/ml of blood (83.3 +/- 6.7 and 121 +/- 6.9, respectively) than 10 microg/kg/day (71.6 +/- 6.5). Mobilization with 6 or 8 microg/kg/12 h of G-CSF was also associated with collection of significantly more CD34+ cells in…

AdultMaleAdolescentmedicine.medical_treatmentBlood volumeHematopoietic stem cell transplantationDrug Administration ScheduleAndrologyGranulocyte Colony-Stimulating FactorHumansTransplantation HomologousMedicinePlateletProgenitor cellChildAgedTransplantationMobilizationbusiness.industryHematopoietic Stem Cell TransplantationHematologyMiddle AgedHematopoietic Stem Cell MobilizationBlood Cell CountGranulocyte colony-stimulating factorTransplantationmedicine.anatomical_structureImmunologyBlood Component RemovalFemaleBone marrowbusinessBone Marrow Transplantation
researchProduct

Hematopoietic responses in patients with advanced malignancy treated with recombinant human granulocyte-macrophage colony-stimulating factor.

1989

The in vivo effect of yeast-derived recombinant human granulocyte-macrophage colony-stimulating factor (rh GM-CSF) was investigated in 30 patients with advanced malignancy in a phase Ib trial. Patients were treated at four different dose levels (120 to 1,000 micrograms/m2/d) by either daily intravenous (IV) bolus injection or 24-hour continuous infusion. Administration of rh GM-CSF resulted in a broad spectrum of dose- and schedule-dependent hematopoietic effects. Sustained infusion of rh GM-CSF elicited a maximum 17-fold average peak increase of the total WBC count with mainly neutrophils, eosinophils, and monocytes accounting for this rise, and increases in bone marrow cellularity with a…

AdultMaleCancer Researchmedicine.medical_specialtyMyeloidAdolescentMicrogramMalignancyDrug Administration ScheduleLeukocyte CountColony-Stimulating FactorsIn vivoBone MarrowInternal medicineNeoplasmsmedicineHumansPlateletLeukocytosisGrowth SubstancesInfusions IntravenousAgedbusiness.industryPlatelet CountGranulocyte-Macrophage Colony-Stimulating FactorMiddle Agedmedicine.diseaseRecombinant ProteinsHematopoiesisHaematopoiesisEndocrinologyGranulocyte macrophage colony-stimulating factormedicine.anatomical_structureOncologyImmunologyInjections IntravenousDrug EvaluationFemalemedicine.symptombusinessmedicine.drugJournal of clinical oncology : official journal of the American Society of Clinical Oncology
researchProduct

CONSISTENT BONE MARROW-DERIVED CELL MOBILIZATION FOLLOWING REPEATED SHORT COURSES OF GRANULOCYTE-COLONY-STIMULATING FACTOR IN PATIENTS WITH AMYOTROPH…

2009

Background and aims. The aim of this study was to evaluate and characterize the feasibility and safety of bone marrow-derived cell (BMC) mobilization following repeated courses of granulocyte-colony stimulating factor (G-CSF) in patients with amyotrophic lateral sclerosis (ALS). Methods. Between January 2006 and March 2007, 26 ALS patients entered a multicenter trial that included four courses of BMC mobilization at 3-month intervals. In each course, G-CSF (5 mu g/kg b.i.d.) was administered for four consecutive days; 18% mannitol was also given. Mobilization was monitored by flow cytometry analysis of circulating CD34(+) cells and by in vitro colony assay for clonogenic progenitors. Co-exp…

AdultMaleCancer Researchmedicine.medical_specialtySLa - trial clinico - C-GSFImmunologyAntigens CD34Bone Marrow CellsDrug Administration ScheduleColony-Forming Units AssayCell MovementInternal medicineMulticenter trialmedicineImmunology and AllergyHumansCell LineageProspective StudiesAmyotrophic lateral sclerosisProspective cohort studyGenetics (clinical)Hematopoietic Stem Cell MobilizationNeuronsTransplantationMobilizationbusiness.industryStem CellsAmyotrophic Lateral SclerosisGranulocyte-Macrophage Colony-Stimulating FactorCell DifferentiationCell BiologyMiddle Agedmedicine.diseaseHematopoietic Stem CellsBone Marrow-Derived CellHematopoietic Stem Cell MobilizationSurgeryGranulocyte colony-stimulating factorNerve RegenerationSettore MED/26 - NEUROLOGIAGranulocyte macrophage colony-stimulating factorTreatment OutcomeOncologyBiological MarkersFemalebusinessNeurogliaBiomarkersmedicine.drug
researchProduct

In Lysinuric Protein Intolerance system y+L activity is defective in monocytes and in GM-CSF-differentiated macrophages

2010

Abstract Background In the recessive aminoaciduria Lysinuric Protein Intolerance (LPI), mutations of SLC7A7/y+LAT1 impair system y+L transport activity for cationic amino acids. A severe complication of LPI is a form of Pulmonary Alveolar Proteinosis (PAP), in which alveolar spaces are filled with lipoproteinaceous material because of the impaired surfactant clearance by resident macrophages. The pathogenesis of LPI-associated PAP remains still obscure. The present study investigates for the first time the expression and function of y+LAT1 in monocytes and macrophages isolated from a patient affected by LPI-associated PAP. A comparison with mesenchymal cells from the same subject has been a…

AdultMaleCellular differentiationlcsh:MedicinePulmonary Alveolar ProteinosisBiologyMonocytesPathogenesisYoung AdultMacrophages AlveolarmedicineHumansGenetics(clinical)Pharmacology (medical)Amino Acid Metabolism Inborn ErrorsCells CulturedGenetics (clinical)Medicine(all)chemistry.chemical_classificationResearchFusion Regulatory Protein 1 Light ChainsLysinelcsh:RMesenchymal stem cellAmino Acid Transport System y+LGranulocyte-Macrophage Colony-Stimulating FactorCell DifferentiationGeneral Medicinemedicine.diseaseLysinuric protein intoleranceMolecular biologyAmino acidGranulocyte macrophage colony-stimulating factorchemistryAminoaciduriaImmunologyPulmonary alveolar proteinosismedicine.drugOrphanet Journal of Rare Diseases
researchProduct

Analgesics use in competitive triathletes: its relationship to doping and on predicting its usage

2016

The two major objectives of this study were (i) to assess variables that predict the use of analgesics in competitive athletes and (ii) to test whether the use of analgesics is associated with the use of doping. A questionnaire primarily addressing the use of analgesics and doping was distributed among 2,997 triathletes. Binary logistic regression analysis was performed to predict the use of analgesics. Moreover, the randomised response technique (RRT) was used to estimate the prevalence of doping in order to assess whether users of analgesics have a higher potential risk for doping than non-users. Statistical power analyses were performed to determine sample size. The bootstrap method was …

AdultMaleCompetitive Behaviormedicine.medical_specialtyPhysical Therapy Sports Therapy and RehabilitationCompetitive athletesPerformance-Enhancing SubstancesStatistical powerRunning03 medical and health sciencesSex Factors0302 clinical medicineRisk FactorsSex factorsSurveys and QuestionnairesStatistical significancePrevalenceHumansMedicineOrthopedics and Sports MedicineBinary logistic regression analysisSwimmingSimulationDoping in SportsAnalgesicsbiologyPotential riskbusiness.industryAthletes030229 sport sciencesMiddle AgedPrecipitating Factorsbiology.organism_classificationBicyclingLogistic ModelsAthletesSample size determinationPhysical therapyFemalebusiness030217 neurology & neurosurgerySportsJournal of Sports Sciences
researchProduct

Inhibition of nitric oxide activity by arginine analogs in human renal arteries

2001

Abstract Background: Plasma levels of endogenous guanidine compounds are increased in various pathologic conditions, including chronic renal failure. In the present study we tested the effects of some of these compounds on basal and stimulated nitric oxide activity in human renal arteries. Methods: Rings from human renal arteries were obtained from 22 patients undergoing nephrectomy. The rings were suspended in organ baths for isometric recording of tension. We then studied the effects of N G -monomethyl- l -arginine (L-NMMA), N G , N G -dimethyl- l -arginine (asymmetrical dimethylarginine [ADMA]), aminoguanidine (AG), and methylguanidine (MG) on artery rings under basal and stimulated cond…

AdultMaleEndothelium-derived hyperpolarizing factormedicine.medical_specialtyArginineArginineNitric OxideNitric oxidechemistry.chemical_compoundRenal ArteryRisk FactorsInternal medicinemedicine.arteryInternal MedicinemedicineHumansEndothelial dysfunctionRenal arteryAgedbusiness.industryMiddle Agedmedicine.diseaseAcetylcholinePimagedinemedicine.anatomical_structureEndocrinologychemistryOmega-N-MethylarginineFemalebusinessBiomarkersArteryAmerican Journal of Hypertension
researchProduct

Effects of Heat Waves on Mortality

2013

Heat waves and air pollution are both associated with increased mortality. Their joint effects are less well understood.We explored the role of air pollution in modifying the effects of heat waves on mortality, within the EuroHEAT project. Daily mortality, meteorologic, and air pollution data from nine European cities for the years 1990-2004 were assembled. We defined heat waves by taking both intensity and duration into account. The city-specific effects of heat wave episodes were estimated using generalized estimating equation models, adjusting for potential confounders with and without inclusion of air pollutants (particles, ozone, nitrogen dioxide, sulphur dioxide, carbon monoxide). To …

AdultMaleHot TemperatureTime FactorsOzoneAdolescentDatabases FactualEpidemiologyNitrogen DioxideAir pollutionmedicine.disease_causeAtmospheric sciencesEffect Modifier EpidemiologicToxicologyYoung Adultchemistry.chemical_compoundOzoneAir pollutantsAir PollutionmedicineHumansSulfur DioxideNitrogen dioxideCitiesMortalityChildWeatherAgedAged 80 and overAir PollutantsCarbon MonoxideConfoundingInfantConfounding Factors EpidemiologicMiddle AgedHeat waveParticulatesEuropechemistryChild PreschoolEnvironmental scienceFemaleParticulate MatterEffect modificationEpidemiology
researchProduct

The quality of plasma collected by automated apheresis and of recovered plasma from leukodepleted whole blood.

2005

Background There exists a current lack of information about the composition of the different types of plasma. No direct comparisons between apheresis plasma (AP) and recovered plasma (RP) derived from in-line-filtered whole blood (WB) have been published to date. Study design and methods Sixty AP units, 100 RP units from in-line-filtered WB held for 3 hours at 20 degrees C between donation and freezing, and an additional 100 RP units held for 15 hours at 20 degrees C before freezing were analyzed for coagulation factors and inhibitors, total protein, immunoglobulin G (IgG), and hemostasis and proteolysis activation markers. The influence of twice freezing and thawing on clotting factors V, …

AdultMaleImmunologyProtein SImmunoglobulin GCitric AcidAndrologyFactor IXLeukocyte CountPlasmaImmunology and AllergyHumansFactor XIWhole bloodClotting factorHemostasisFactor VIIIbiologyChemistryAnticoagulantsFactor VFibrinogenHematologyMiddle AgedApheresisCoagulationHemostasisImmunologybiology.proteinBlood Component RemovalFemaleLeukocyte ElastasePlatelet factor 4Transfusion
researchProduct

Weekly Dose-Dense Cisplatin-Epirubicin-Paclitaxel Administration with Granulocyte Colony-Stimulating Factor Support Does Not Substantially Improve Pr…

2004

Purpose: The present study was aimed at defining the antitumor activity of the cisplatin-epirubicin-paclitaxel (PET) weekly administration with granulocyte colony-stimulating factor (G-CSF) support in chemonaive small-cell lung cancer patients with extensive disease (ED-SCLC). Methods: Chemonaive ED-SCLC patients received cisplatin 30 mg/sqm, epirubicin 50 mg/sqm and paclitaxel 120 mg/sqm, weekly, with G-CSF (5 μg/kg from day 3 to 5) support, for a maximum of 12 weeks. Results: Thirty-nine patients were treated, for a total of 354 cycles delivered. Eight complete (21%), and 22 partial responses (56%) were recorded, giving a 77% (95% Cl = 61-89%) objective response rate (ORR). After 14 (rang…

AdultMaleLung NeoplasmsPaclitaxelMiddle AgedPrognosisSmall-cell lung cancer Weekly chemotherapy Paclitaxel Epirubicin CisplatinSurvival AnalysisDrug Administration ScheduleTreatment OutcomeAntineoplastic Combined Chemotherapy ProtocolsGranulocyte Colony-Stimulating FactorHumansFemaleCarcinoma Small CellCisplatinInfusions IntravenousAgedEpirubicin
researchProduct